Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,814,956 papers from all fields of science
Search
Sign In
Create Free Account
tesetaxel
A semi-synthetic, orally bioavailable taxane derivative with potential antineoplastic and antiangiogenic properties. Tesetaxel binds to and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Narrower (1)
DJ927
Microtubule Process
NCIt Antineoplastic Agent Terminology
Broader (1)
Taxoids
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally…
J. O’Shaughnessy
,
M. Piccart
,
+16 authors
A. Seidman
Journal of Clinical Oncology
2019
Corpus ID: 190901287
TPS1107 Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. Tesetaxel (T) is a…
Expand
2018
2018
Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).
J. O’Shaughnessy
,
M. Piccart-Gebhart
,
+17 authors
A. Seidman
2018
Corpus ID: 81017897
TPS1106Background: Chemotherapy treatments that offer improved quality of life are needed. Tesetaxel (T) is a novel, oral taxane…
Expand
2011
2011
P5-19-11: Tesetaxel, an Oral Taxane, as First-Line Therapy for Women with Metastatic Breast Cancer.
L. Schwartzberg
,
P. Rubin
,
A. Patnaik
,
L. Itri
,
A. Olson
,
A. Seidman
2011
Corpus ID: 73059030
Background Parenteral taxanes (docetaxel, paclitaxel) are among the most active agents in treating metastatic breast cancer (MBC…
Expand
2010
2010
Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding agent.
M. Beeram
,
Kyri Papadopoulos
,
A. Patnaik
,
A. Qureshi
,
A. Tolcher
2010
Corpus ID: 74212770
e13075 Background: Currently approved taxanes are given intravenously and associated with marked hypersensitivity and cumulative…
Expand
2010
2010
An intersubject dose-escalation study of tesetaxel administered orally once every 3 weeks and once weekly for 3 consecutive weeks in patients with advanced or metastatic solid tumors.
M. Beeram
,
S. Novick
,
A. Qureshi
,
A. Patnaik
,
K. Papadopoulos
,
A. Tolcher
2010
Corpus ID: 75221749
TPS159 Background: Tesetaxel is an orally active tubulin-binding inhibitor that has completed multiple phase II trials. In…
Expand